Back

Rationale for and design of the SUBQ-HF clinical study.

21 May 2016 (13:30 - 13:45)
Organised by:
Congress Presentation Part of: Furosemide 2.0: furosemide for subcutaneous administration: a novel tool in the management of the pre and post acute heart failure patient Acute Heart Failure HFA Premium Access HEART FAILURE 2016

About the speaker

Photo
Professor G Michael Felker

Duke University Medical Center, Durham (United States of America)

3 More presentations in this session

Presentation thumbnail
Furosemide 2.0: a novel formulation of furosemide for subcutaneous administration.
Professor B. Pitt (Ann Arbor, US)
Presentation thumbnail
Pharmacokinetics of furosemide following subcutaneous administration of a novel injectable formulation.
Professor R. De Boer (Rotterdam, NL)
Presentation thumbnail
Initial clinical experience with subcutaneous furosemide in patients with fluid overload.
Doctor S. Russell (Durham, US)

Access the full session

Session thumbnail
Furosemide 2.0: furosemide for subcutaneous administration: a novel tool in the management of the pre and post acute heart failure patient

The Event

Event poster

HEART FAILURE 2016

21 May 2016 13:30 CET
You may be interested in
thumbnail
Congress Session
Late-Breaking Clinical Trials - Pharmacotherapy
21 May 2022
thumbnail
Congress Session
Evolving treatment paradigms in heart failure: from SGLT2 inhibition to transthyretin stabilisation and beyond
20 May 2025
thumbnail
Congress Presentation
Real-life evidence of the use of subcutaneous treprostinil in pulmonary hypertension in Argentina
1 July 2021
thumbnail
Webinar
The EAPCI Journal Club - RESHAPE-HF2: percutaneous repair of moderate-to-severe or severe functional mitral regurgitation in patients with symptomatic heart failure
5 November 2024

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources